Cargando…

Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro

This report describes the application of real-time PCR for testing antivirals against highly pathogenic viruses such as Lassa virus, SARS coronavirus and Ebola virus. The test combines classical cell culture with a quantitative real-time PCR read-out. The assay for Lassa virus was validated with rib...

Descripción completa

Detalles Bibliográficos
Autores principales: Günther, Stephan, Asper, Marcel, Röser, Christina, Luna, Luciano K.S., Drosten, Christian, Becker-Ziaja, Beate, Borowski, Peter, Chen, Huan-Ming, Hosmane, Ramachandra S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126008/
https://www.ncbi.nlm.nih.gov/pubmed/15451189
http://dx.doi.org/10.1016/j.antiviral.2004.05.001
_version_ 1783516064362004480
author Günther, Stephan
Asper, Marcel
Röser, Christina
Luna, Luciano K.S.
Drosten, Christian
Becker-Ziaja, Beate
Borowski, Peter
Chen, Huan-Ming
Hosmane, Ramachandra S.
author_facet Günther, Stephan
Asper, Marcel
Röser, Christina
Luna, Luciano K.S.
Drosten, Christian
Becker-Ziaja, Beate
Borowski, Peter
Chen, Huan-Ming
Hosmane, Ramachandra S.
author_sort Günther, Stephan
collection PubMed
description This report describes the application of real-time PCR for testing antivirals against highly pathogenic viruses such as Lassa virus, SARS coronavirus and Ebola virus. The test combines classical cell culture with a quantitative real-time PCR read-out. The assay for Lassa virus was validated with ribavirin, which showed an IC(50) of 9 μg/ml. Small-scale screening identified a class of imidazole nucleoside/nucleotide analogues with antiviral activity against Lassa virus. The analogues contained either dinitrile or diester groups at the imidazole 4,5-positions, and many of which possessed an acyclic sugar or sugar phosphonate moiety at the imidazole 1-position. The IC(50) values of the most active compounds ranged from 5 to 21 μg/ml. The compounds also inhibited replication of SARS coronavirus and Ebola virus in analogous assays, although to a lesser extent than Lassa virus.
format Online
Article
Text
id pubmed-7126008
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71260082020-04-08 Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro Günther, Stephan Asper, Marcel Röser, Christina Luna, Luciano K.S. Drosten, Christian Becker-Ziaja, Beate Borowski, Peter Chen, Huan-Ming Hosmane, Ramachandra S. Antiviral Res Short Communication This report describes the application of real-time PCR for testing antivirals against highly pathogenic viruses such as Lassa virus, SARS coronavirus and Ebola virus. The test combines classical cell culture with a quantitative real-time PCR read-out. The assay for Lassa virus was validated with ribavirin, which showed an IC(50) of 9 μg/ml. Small-scale screening identified a class of imidazole nucleoside/nucleotide analogues with antiviral activity against Lassa virus. The analogues contained either dinitrile or diester groups at the imidazole 4,5-positions, and many of which possessed an acyclic sugar or sugar phosphonate moiety at the imidazole 1-position. The IC(50) values of the most active compounds ranged from 5 to 21 μg/ml. The compounds also inhibited replication of SARS coronavirus and Ebola virus in analogous assays, although to a lesser extent than Lassa virus. Elsevier B.V. 2004-09 2004-06-15 /pmc/articles/PMC7126008/ /pubmed/15451189 http://dx.doi.org/10.1016/j.antiviral.2004.05.001 Text en Copyright © 2004 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Günther, Stephan
Asper, Marcel
Röser, Christina
Luna, Luciano K.S.
Drosten, Christian
Becker-Ziaja, Beate
Borowski, Peter
Chen, Huan-Ming
Hosmane, Ramachandra S.
Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro
title Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro
title_full Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro
title_fullStr Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro
title_full_unstemmed Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro
title_short Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro
title_sort application of real-time pcr for testing antiviral compounds against lassa virus, sars coronavirus and ebola virus in vitro
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126008/
https://www.ncbi.nlm.nih.gov/pubmed/15451189
http://dx.doi.org/10.1016/j.antiviral.2004.05.001
work_keys_str_mv AT guntherstephan applicationofrealtimepcrfortestingantiviralcompoundsagainstlassavirussarscoronavirusandebolavirusinvitro
AT aspermarcel applicationofrealtimepcrfortestingantiviralcompoundsagainstlassavirussarscoronavirusandebolavirusinvitro
AT roserchristina applicationofrealtimepcrfortestingantiviralcompoundsagainstlassavirussarscoronavirusandebolavirusinvitro
AT lunalucianoks applicationofrealtimepcrfortestingantiviralcompoundsagainstlassavirussarscoronavirusandebolavirusinvitro
AT drostenchristian applicationofrealtimepcrfortestingantiviralcompoundsagainstlassavirussarscoronavirusandebolavirusinvitro
AT beckerziajabeate applicationofrealtimepcrfortestingantiviralcompoundsagainstlassavirussarscoronavirusandebolavirusinvitro
AT borowskipeter applicationofrealtimepcrfortestingantiviralcompoundsagainstlassavirussarscoronavirusandebolavirusinvitro
AT chenhuanming applicationofrealtimepcrfortestingantiviralcompoundsagainstlassavirussarscoronavirusandebolavirusinvitro
AT hosmaneramachandras applicationofrealtimepcrfortestingantiviralcompoundsagainstlassavirussarscoronavirusandebolavirusinvitro